In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Omeros Corporation

http://www.omeros.com/

Latest From Omeros Corporation

Finance Watch: Ascendis Spins Out Ophthalmology Firm Eyconis With $150m

Private Company Edition: Publicly held Ascendis outsourced its preclinical AMD program to private Eyconis. Also, Innovation Endeavors revealed a new $630m VC fund and Mirae raised $50m for its first life science fund, while Accent, Comanche and Tr1X each brought in $75m rounds.

Financing Innovation

Genentech Places Bet On Polymer Nanoparticle-Based Delivery With GenEdit Deal

Deal Snapshot: The Roche subsidiary will use GenEdit’s hydrophilic nanoparticles to develop genetic medicines for autoimmune diseases meant to overcome the limitations of existing delivery methods.

Deals Gene Therapy

Omeros Crashes To All-Time Low On IgAN Failure

Development of narsoplimab in the kidney disease has been called off, making a forthcoming regulatory decision in a different use all the more important.

Clinical Trials Companies

Muted APPLAUSE For Novartis In IgAN

A Phase III hit is always nice but a lot more information will be required to judge iptacopan’s market potential.

Clinical Trials Renal
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register